Octamoxin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Octamoxin
Accession Number
DB09249
Type
Small Molecule
Groups
Withdrawn
Description

Octamoxin (trade names Ximaol, Nimaol), also known as 2-octylhydrazine, is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant in the 1960s but is now no longer marketed.

Structure
Thumb
Synonyms
  • 2-octylhydrazine
International/Other Brands
Nimaol / Ximaol
Categories
UNII
0HXY3M6S54
CAS number
4684-87-1
Weight
Average: 144.262
Monoisotopic: 144.162648652
Chemical Formula
C8H20N2
InChI Key
FODQIVGFADUBKE-UHFFFAOYSA-N
InChI
InChI=1S/C8H20N2/c1-3-4-5-6-7-8(2)10-9/h8,10H,3-7,9H2,1-2H3
IUPAC Name
(octan-2-yl)hydrazine
SMILES
CCCCCCC(C)NN

Pharmacology

Indication

For the treatment of depression.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineOctamoxin may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineOctamoxin may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineOctamoxin may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Octamoxin.Experimental
AcarboseOctamoxin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololOctamoxin may increase the hypotensive activities of Acebutolol.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Octamoxin.Experimental
AlbiglutideOctamoxin may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Octamoxin.Approved, Illicit
AliskirenOctamoxin may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Octamoxin.Approved, Investigational
AlogliptinOctamoxin may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Octamoxin.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Octamoxin.Illicit
AlprenololOctamoxin may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Octamoxin.Approved
AmbrisentanOctamoxin may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineOctamoxin may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineOctamoxin may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineOctamoxin may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Amoxapine.Approved
AmphetamineOctamoxin may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Octamoxin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Arformoterol.Approved, Investigational
AtenololOctamoxin may increase the hypotensive activities of Atenolol.Approved
AtomoxetineOctamoxin may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineOctamoxin may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Bambuterol.Approved
BenazeprilOctamoxin may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideOctamoxin may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Octamoxin.Withdrawn
BenzphetamineOctamoxin may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilOctamoxin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Octamoxin.Approved
BetaxololOctamoxin may increase the hypotensive activities of Betaxolol.Approved
BethanidineOctamoxin may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Octamoxin is combined with Bezafibrate.Approved
BietaserpineOctamoxin may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostOctamoxin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololOctamoxin may increase the hypotensive activities of Bisoprolol.Approved
BosentanOctamoxin may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Octamoxin may increase the hypotensive activities of BQ-123.Investigational
BretyliumOctamoxin may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Brimonidine.Approved
BrofaromineBrofaromine may increase the hypertensive activities of Octamoxin.Experimental
BromocriptineOctamoxin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BupranololOctamoxin may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Octamoxin.Approved, Illicit, Investigational, Vet Approved
BupropionOctamoxin may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Octamoxin.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Octamoxin.Approved, Illicit, Vet Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Octamoxin.Approved
CadralazineOctamoxin may increase the hypotensive activities of Cadralazine.Experimental
CafedrineOctamoxin may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinOctamoxin may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanOctamoxin may increase the hypotensive activities of Candesartan.Approved
CandoxatrilOctamoxin may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilOctamoxin may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Octamoxin.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Octamoxin.Illicit, Vet Approved
CaroxazoneOctamoxin may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololOctamoxin may increase the hypotensive activities of Carteolol.Approved
CarvedilolOctamoxin may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololOctamoxin may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideOctamoxin may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineOctamoxin may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamideOctamoxin may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneOctamoxin may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineOctamoxin may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilOctamoxin may increase the hypotensive activities of Cilazapril.Approved
CirazolineOctamoxin may increase the hypertensive activities of Cirazoline.Experimental
CitalopramOctamoxin may increase the serotonergic activities of Citalopram.Approved
ClemastineOctamoxin may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Clenbuterol.Approved, Vet Approved
ClomipramineOctamoxin may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidineOctamoxin may increase the hypotensive activities of Clonidine.Approved
CloranololOctamoxin may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Octamoxin.Approved, Illicit
CryptenamineOctamoxin may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Octamoxin.Approved
CyclopenthiazideOctamoxin may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideOctamoxin may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineOctamoxin may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinOctamoxin may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineOctamoxin may increase the serotonergic activities of Dapoxetine.Investigational
DebrisoquinOctamoxin may increase the hypotensive activities of Debrisoquin.Approved
DelaprilOctamoxin may increase the hypotensive activities of Delapril.Experimental
DeserpidineOctamoxin may increase the hypotensive activities of Deserpidine.Approved
DesipramineOctamoxin may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxineOctamoxin may increase the serotonergic activities of Desvenlafaxine.Approved
DexmethylphenidateOctamoxin may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineOctamoxin may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanOctamoxin may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Octamoxin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Octamoxin.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Octamoxin.Approved
DiazoxideOctamoxin may increase the hypotensive activities of Diazoxide.Approved
DibenzepinOctamoxin may increase the serotonergic activities of Dibenzepin.Experimental
diethylnorspermineOctamoxin may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionOctamoxin may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineOctamoxin may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Octamoxin.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Octamoxin.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Octamoxin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Octamoxin.Experimental, Illicit
DiltiazemOctamoxin may increase the hypotensive activities of Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Octamoxin.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Dipivefrin.Approved
DisopyramideOctamoxin may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Octamoxin is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideOctamoxin may increase the hypotensive activities of Dorzolamide.Approved
DosulepinOctamoxin may increase the serotonergic activities of Dosulepin.Approved
DoxapramOctamoxin may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinOctamoxin may increase the hypotensive activities of Doxazosin.Approved
DoxepinOctamoxin may increase the serotonergic activities of Doxepin.Approved
DoxylamineOctamoxin may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Octamoxin.Investigational
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Octamoxin.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Octamoxin is combined with Droxidopa.Approved, Investigational
DulaglutideOctamoxin may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineOctamoxin may increase the serotonergic activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Octamoxin.Experimental, Illicit
EfonidipineOctamoxin may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Octamoxin.Approved, Investigational
EmpagliflozinOctamoxin may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilOctamoxin may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatOctamoxin may increase the hypotensive activities of Enalaprilat.Approved
EndralazineOctamoxin may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Octamoxin.Approved, Investigational
EpanololOctamoxin may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Octamoxin is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpoprostenolOctamoxin may increase the hypotensive activities of Epoprostenol.Approved
EprosartanOctamoxin may increase the hypotensive activities of Eprosartan.Approved
ErgotamineOctamoxin may increase the hypertensive activities of Ergotamine.Approved
EscitalopramOctamoxin may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineOctamoxin may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Octamoxin.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Octamoxin.Approved, Illicit
EtoperidoneOctamoxin may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Octamoxin.Illicit, Vet Approved
ExenatideOctamoxin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineOctamoxin may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamOctamoxin may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Fenoterol.Approved
FentanylFentanyl may increase the serotonergic activities of Octamoxin.Approved, Illicit, Investigational, Vet Approved
Ferulic acidOctamoxin may increase the hypotensive activities of Ferulic acid.Experimental
FluoxetineOctamoxin may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxamineOctamoxin may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Formoterol.Approved, Investigational
FosinoprilOctamoxin may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Octamoxin.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Octamoxin.Approved, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Octamoxin.Experimental
GliclazideOctamoxin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideOctamoxin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideOctamoxin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideOctamoxin may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzOctamoxin may increase the hypotensive activities of Guanabenz.Approved
GuanadrelOctamoxin may increase the hypotensive activities of Guanadrel.Approved
GuanazodineOctamoxin may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineOctamoxin may increase the hypotensive activities of Guanethidine.Approved
GuanfacineOctamoxin may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorOctamoxin may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzOctamoxin may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanOctamoxin may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypertensive activities of Octamoxin.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Octamoxin.Approved, Illicit
HexamethoniumOctamoxin may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineHydracarbazine may increase the hypertensive activities of Octamoxin.Experimental
HydralazineOctamoxin may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideOctamoxin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Octamoxin is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideOctamoxin may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Octamoxin is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineOctamoxin may increase the hypertensive activities of Hydroxyamphetamine.Approved
ImidaprilOctamoxin may increase the hypotensive activities of Imidapril.Investigational
ImipramineOctamoxin may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Indacaterol.Approved
IndalpineOctamoxin may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideOctamoxin may increase the hypotensive activities of Indapamide.Approved
IndenololOctamoxin may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminOctamoxin may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartOctamoxin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirOctamoxin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineOctamoxin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineOctamoxin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanOctamoxin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproOctamoxin may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Octamoxin.Approved
IprindoleOctamoxin may increase the serotonergic activities of Iprindole.Experimental
IproclozideIproclozide may increase the hypertensive activities of Octamoxin.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Octamoxin.Withdrawn
IrbesartanOctamoxin may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Octamoxin.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Octamoxin is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Isoprenaline.Approved
IsradipineOctamoxin may increase the hypotensive activities of Isradipine.Approved
KetanserinOctamoxin may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Octamoxin.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Octamoxin.Approved, Nutraceutical, Withdrawn
LabetalolOctamoxin may increase the hypotensive activities of Labetalol.Approved
LacidipineOctamoxin may increase the hypotensive activities of Lacidipine.Approved
LatanoprostOctamoxin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineOctamoxin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Octamoxin.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Octamoxin.Approved
LevomilnacipranOctamoxin may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinOctamoxin may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Octamoxin.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Levosalbutamol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Octamoxin is combined with Linezolid.Approved, Investigational
LinsidomineOctamoxin may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideOctamoxin may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineOctamoxin may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilOctamoxin may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Octamoxin.Approved
LithiumThe risk or severity of adverse effects can be increased when Octamoxin is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Octamoxin.Illicit
LofepramineOctamoxin may increase the serotonergic activities of Lofepramine.Experimental
LofexidineOctamoxin may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanOctamoxin may increase the hypotensive activities of Losartan.Approved
MacitentanOctamoxin may increase the hypotensive activities of Macitentan.Approved
ManidipineOctamoxin may increase the hypotensive activities of Manidipine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Octamoxin.Approved
MebanazineMebanazine may increase the hypertensive activities of Octamoxin.Withdrawn
MecamylamineOctamoxin may increase the hypotensive activities of Mecamylamine.Approved
MecaserminOctamoxin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedroneOctamoxin may increase the hypertensive activities of Mephedrone.Investigational
MephentermineOctamoxin may increase the hypertensive activities of Mephentermine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Octamoxin.Experimental
MequitazineOctamoxin may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolOctamoxin may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminOctamoxin may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Octamoxin is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Octamoxin.Approved, Illicit
MethamphetamineOctamoxin may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoserpidineOctamoxin may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineOctamoxin may increase the hypertensive activities of Methoxamine.Approved
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Octamoxin.Experimental
MethyldopaThe risk or severity of adverse effects can be increased when Octamoxin is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Octamoxin.Experimental
Methylene blueOctamoxin may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateOctamoxin may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetipranololOctamoxin may increase the hypotensive activities of Metipranolol.Approved
MetolazoneOctamoxin may increase the hypotensive activities of Metolazone.Approved
MetoprololOctamoxin may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineOctamoxin may increase the hypotensive activities of Metyrosine.Approved
MianserinOctamoxin may increase the neurotoxic activities of Mianserin.Approved
MibefradilOctamoxin may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineOctamoxin may increase the hypertensive activities of Midodrine.Approved
MidomafetamineOctamoxin may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MifepristoneOctamoxin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolOctamoxin may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranOctamoxin may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Octamoxin.Approved
MinoxidilOctamoxin may increase the hypotensive activities of Minoxidil.Approved
MirtazapineOctamoxin may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAOctamoxin may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Octamoxin is combined with Moclobemide.Approved
MoexiprilOctamoxin may increase the hypotensive activities of Moexipril.Approved
MoxonidineOctamoxin may increase the hypotensive activities of Moxonidine.Approved
MuzolimineOctamoxin may increase the hypotensive activities of Muzolimine.Experimental
NadololOctamoxin may increase the hypotensive activities of Nadolol.Approved
NaftopidilOctamoxin may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Octamoxin.Approved
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Octamoxin.Approved, Investigational
NateglinideOctamoxin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololOctamoxin may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneOctamoxin may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Octamoxin.Withdrawn
NicardipineOctamoxin may increase the hypotensive activities of Nicardipine.Approved
NicorandilOctamoxin may increase the hypotensive activities of Nicorandil.Approved
NiguldipineOctamoxin may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineOctamoxin may increase the hypotensive activities of Nilvadipine.Approved
NimodipineOctamoxin may increase the hypotensive activities of Nimodipine.Approved
NisoldipineOctamoxin may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineOctamoxin may increase the hypotensive activities of Nitrendipine.Approved
NitroprussideOctamoxin may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineOctamoxin may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Octamoxin.Approved, Illicit
NortriptylineOctamoxin may increase the serotonergic activities of Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Olanzapine.Approved, Investigational
OlmesartanOctamoxin may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Olodaterol.Approved
OmapatrilatOctamoxin may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolOctamoxin may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Octamoxin.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Orciprenaline.Approved
OxprenololOctamoxin may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Octamoxin is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Octamoxin.Approved, Investigational, Vet Approved
PargylineOctamoxin may increase the hypotensive activities of Pargyline.Approved
ParoxetineOctamoxin may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololOctamoxin may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineOctamoxin may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Octamoxin.Approved, Vet Approved
PentoliniumOctamoxin may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Octamoxin.Approved, Vet Approved, Withdrawn
PerindoprilOctamoxin may increase the hypotensive activities of Perindopril.Approved
PethidineOctamoxin may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Octamoxin.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Octamoxin.Approved
PheniprazineOctamoxin may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Octamoxin.Experimental
PhenoxybenzamineOctamoxin may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineOctamoxin may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineOctamoxin may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineOctamoxin may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineOctamoxin may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Octamoxin.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Octamoxin.Investigational
PinacidilOctamoxin may increase the hypotensive activities of Pinacidil.Withdrawn
PindololOctamoxin may increase the hypotensive activities of Pindolol.Approved
PioglitazoneOctamoxin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Octamoxin.Investigational
PirlindolePirlindole may increase the hypertensive activities of Octamoxin.Approved
PivhydrazineOctamoxin may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenOctamoxin may increase the anticholinergic activities of Pizotifen.Approved
PolythiazideOctamoxin may increase the hypotensive activities of Polythiazide.Approved
PramlintideOctamoxin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinOctamoxin may increase the hypotensive activities of Prazosin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Procaterol.Approved
PropranololOctamoxin may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineOctamoxin may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Octamoxin.Investigational
PseudoephedrineOctamoxin may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilOctamoxin may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineOctamoxin may increase the hypoglycemic activities of Quinine.Approved
RamiprilOctamoxin may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Octamoxin.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Octamoxin.Approved
RemikirenOctamoxin may increase the hypotensive activities of Remikiren.Approved
RepaglinideOctamoxin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineOctamoxin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Reserpine.Approved
RilmenidineOctamoxin may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatOctamoxin may increase the hypotensive activities of Riociguat.Approved
RitobegronOctamoxin may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Ritodrine.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Octamoxin.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Octamoxin.Approved, Investigational
RosiglitazoneOctamoxin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineOctamoxin may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Salmeterol.Approved
SaprisartanOctamoxin may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinOctamoxin may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Octamoxin.Approved, Investigational, Vet Approved
SelexipagOctamoxin may increase the hypotensive activities of Selexipag.Approved
SertralineOctamoxin may increase the serotonergic activities of Sertraline.Approved
SitagliptinOctamoxin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanOctamoxin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilOctamoxin may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of Octamoxin.Approved, Investigational
SulfadiazineOctamoxin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleOctamoxin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleOctamoxin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Octamoxin.Approved, Investigational
SunitinibOctamoxin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololOctamoxin may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Octamoxin.Approved
TelmisartanOctamoxin may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilOctamoxin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Terbutaline.Approved
TerlipressinOctamoxin may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Octamoxin.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Octamoxin.Approved
TetrahydropalmatineOctamoxin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineOctamoxin may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineOctamoxin may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Octamoxin.Approved
TiboloneOctamoxin may increase the hypotensive activities of Tibolone.Approved
TicrynafenOctamoxin may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Octamoxin.Experimental
TimololOctamoxin may increase the hypotensive activities of Timolol.Approved
TolazamideOctamoxin may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineOctamoxin may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideOctamoxin may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Octamoxin.Approved, Withdrawn
TolonidineOctamoxin may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Octamoxin.Approved
TorasemideOctamoxin may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Octamoxin.Approved, Investigational
TrandolaprilOctamoxin may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Octamoxin.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Octamoxin.Approved
TravoprostOctamoxin may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Octamoxin is combined with Trazodone.Approved, Investigational
TreprostinilOctamoxin may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideOctamoxin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinOctamoxin may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanOctamoxin may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineOctamoxin may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneOctamoxin may increase the hypotensive activities of Unoprostone.Approved
UrapidilOctamoxin may increase the hypotensive activities of Urapidil.Investigational
ValsartanOctamoxin may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineOctamoxin may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Octamoxin.Approved
VincamineOctamoxin may increase the hypotensive activities of Vincamine.Experimental
VinpocetineOctamoxin may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Octamoxin.Approved
XipamideOctamoxin may increase the hypotensive activities of Xipamide.Experimental
XylometazolineOctamoxin may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineOctamoxin may increase the serotonergic activities of Zimelidine.Withdrawn
ZofenoprilOctamoxin may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Octamoxin.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
  1. Gayral L, Stern H, Puyuelo R: [Indications and results of the treatment of mental depression by octamoxine (ximaol)]. Therapie. 1966 Sep-Oct;21(5):1183-90. [PubMed:5976767 ]
External Links
PubChem Compound
20811
PubChem Substance
310265152
ChemSpider
19587
ChEBI
134768
ChEMBL
CHEMBL2104528
Wikipedia
Octamoxin
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.27 mg/mLALOGPS
logP2.54ALOGPS
logP2.26ChemAxon
logS-1.4ALOGPS
pKa (Strongest Basic)5.92ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area38.05 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity56.99 m3·mol-1ChemAxon
Polarizability19.11 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of chemical entities known as alkylhydrazines. These are organonitrogen compounds that containing a hydrazine group to which an alkyl group is attached.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Organic nitrogen compounds
Sub Class
Organonitrogen compounds
Direct Parent
Alkylhydrazines
Alternative Parents
Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Alkylhydrazine / Organopnictogen compound / Hydrocarbon derivative / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 22:02 / Updated on October 02, 2017 06:14